
Opinion|Videos|May 15, 2025
Using RxPONDER Findings to Inform Testing and Treatment Approaches in Node-Positive Breast Cancer
Panelists discuss how the RxPONDER trial data transformed breast cancer treatment by demonstrating that postmenopausal women with 1 to 3 positive lymph nodes and low recurrence scores could safely avoid chemotherapy, while highlighting the controversy about chemotherapy benefit in premenopausal patients where clinical judgment and nuanced assessment of menopausal status remain crucial.
Advertisement
Genomic Testing in Node-Positive Disease
Main Discussion Topics:
- Interpretation of RxPONDER trial results for node-positive patients
- Differing approaches to premenopausal vs postmenopausal patients with node-positive disease
- Role of clinical judgment in treatment decisions
Key Points for Physicians:
- RxPONDER data showed that postmenopausal women with 1 to 3 positive nodes and low recurrence scores can safely avoid chemotherapy.
- Premenopausal women with positive nodes showed small but statistically significant chemotherapy benefit, requiring a nuanced approach.
- Clinical factors beyond age (proximity to menopause, family menopause history) should inform decisions.
Notable Insights:
- Treating all premenopausal patients with node-positive disease with chemotherapy regardless of recurrence score represents a “leap back to 1990.”
- For patients 45 to 50 years old who are perimenopausal, genomic testing still provides valuable information for shared decision-making.
Clinical Significance: Genomic testing remains valuable in node-positive disease but requires integration with clinical judgment and patient preferences, particularly for premenopausal patients for whom benefit may be modest.
Advertisement
Related to this article

The FDA has approved neladalkib for previously treated, ALK-positive, locally adanced or metastatic non-small cell lung cancer.

Roswell Park researchers found CD83 CAR T cells could overcome CD19-targeted therapy resistance in preclinical models of B-cell cancers.

Ryan J. Sullivan, MD, discusses HLA testing, liver-directed therapy, and emerging targeted and T-cell–based therapies for metastatic uveal melanoma.

Pertuzumab-qcay is FDA approved for the 3 HER2-positive breast cancer indications of reference pertuzumab.

The European Commission approved daraxonrasib monotherapy for metastatic pancreatic adenocarcinoma after at least 1 prior systemic therapy.

Cretostimogene improved RFS after tumor resection in PIVOT-006, supporting a planned FDA submission for NMIBC.

The FDA approved giredestrant plus everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
Daraxonrasib Gains EC Approval in Previously Treated Metastatic Pancreatic Cancer
2
Pertuzumab Biosimilar Gains FDA Approval for HER2+ Breast Cancer
3
Dr Cortes on the Rationale Behind the OPTIC Trial in CML
4
Localized Prostate Cancer 2026 UPDATE: PSMA PET, ARPI Strategies, and New Trials Reshape Localized Management
5

